Congress Materials – Digestive Disease Week (DDW 2026)
2026 Digestive Disease Week Annual Meeting | May 2-5 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
ARGES-UC: AI-Based Continuous Scoring For Disease Severity in Ulcerative Colitis Enhances Detection of Treatment Effects and Reduces Sample Size Requirements in Clinical Trials For Measuring Endoscopic Treatment Differences
Pooya Mobadersany, Krishna Chaitanya, Chaitanya Parmar, Yuliya Halchenko, Shinobu Yamamoto, Lindsey Surace, Shadi Yarandi, Nicholas Skomrock, Louis Ghanem, Gabriela Cula, Tommaso Mansi, Kristopher Standish, Pablo Damasceno
This document will be available on May 2 2026
ARGES-Ulcer Percentage-Score: A Continuous, AI-Derived Ulcer Burden Score Correlating with Clinical and Treatment Response Measures in Crohn’s Disease
Krishna Chaitanya, Fabio Gunderson, Lukas Hirsch, Pooya Mobadersany, Chaitanya Parmar, Brendon Lutnick, Shinoboyu Yamamoto, Yuliya Halchenko, Nicholas Skomrock, Shadi Yarandi, Lindsey Surace, Louis Ghanem, Tommaso Mansi, Gabriela Oana Cula, Kristopher Standish, Pablo Damasceno, Michael Rice, Ryan Stidham, Tadd Hiatt
This document will be available on May 2 2026
ARGES-Ulcer-Surface-Score: A Continuous AI-Derived SES-CD Subcomponent for Crohn’s Disease Severity Assessment and Clinical Endpoint Recapitulation
Lukas Hirsch, Krishna Chaitanya, Fabio Gunderson, Pooya Mobadersany, Chaitanya Parmar, Lindsey Surace, Shadi Yarandi, Louis Ghanem, Yuliya Halchenko, Nicholas Skomrock, Tommaso Mansi, Gabriela Cula, Pablo Damasceno, Kristopher Standish
This document will be available on May 2 2026
ARGES-Ulcer: A High-Performance, Generalizable AI Model for Ulcer Segmentation in Crohn’s Disease (CD) from Endoscopy Videos
Krishna Chaitanya, Fabio Gunderson, Lukas Hirsch, Pooya Mobadersany, Chaitanya Parmar, Brendon Lutnick, Shinoboyu Yamamoto, Yuliya Halchenko, Nicholas Skomrock, Shadi Yarandi, Lindsey Surace, Louis Ghanem, Tommaso Mansi, Gabriela Oana Cula, Kristopher Standish, Pablo Damasceno, Michael Rice, Ryan Stidham, Tadd Hiatt
This document will be available on May 2 2026
Association of Endoscopic, Histologic, and Composite Outcomes With Long-Term Guselkumab Efficacy in Ulcerative Colitis: 2-Year Results From the QUASAR Long-Term Extension
Fernando Magro, David T. Rubin, Gary R. Lichtenstein, Yelina Alvarez, Thomas Baker, Ye Miao, Laurent Peyrin-Biroulet
This document will be available on May 2 2026
Dose Escalation in Participants with Primary/Secondary Loss of Response to Conventional Dosing of Ustekinumab in Paediatric Crohn’s Disease (UNITI Jr Study)
Richard K. Russell, Elisabeth De Greef, Dan Turner, Jeffrey S. Hyams,4 Anne M. Griffiths, Stanley A. Cohen, Joel R. Rosh, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Edaire Cheng, Richard Strauss, Els Van Limbergen, Laurie S. Conklin, Omoniyi J. Adedokun, Lilianne Kim, Sheri Volger
This document will be available on May 2 2026
Efficacy and Safety of Guselkumab For Ulcerative Colitis Through Week 140 of the QUASAR Long-Term Extension Study
Laurent Peyrin-Biroulet, Brian Bressler, Axel Dignass, Tadakazu Hisamatsu, Bruce E. Sands, Yelina Alvarez, Thomas Baker, Nicole Shipitofsky, Ye Miao, Hongyan Zhang, Gary R. Lichtenstein, David T. Rubin, Jessica R. Allegretti
This document will be available on May 2 2026
Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn’s Disease Who Had Maintenance Dose Adjustment: Results From the Phase 3 GALAXI 2 & 3 Long-Term Extension
Remo Panaccione, Tadakazu Hisamatsu, Anita Afzali, Rian Van Rampelbergh, Jacqueline Yee, Wilhelmus van Duijnhoven, Christopher Corbett, Bruce E. Sands, Silvio Danese
This document will be available on May 2 2026
Efficacy and Safety of the First Co-Antibody Therapy, JNJ-78934804, in Patients With Moderately to Severely Active Crohn’s Disease Refractory to Systemic Therapies
Bruce E. Sands, Geert D'Haens, Iris Dotan, Nat A. Terry, Monica Walker, Vanessa Bundy, Hayley Perry, Marion L. Vetter, Taku Kobayashi, Stefan Schreiber, Vipul Jairath
This document will be available on May 2 2026
Efficacy and Safety of the First Co-Antibody Therapy, JNJ-78934804, in Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Systemic Therapies
Maria T. Abreu, Bruce E. Sands, Séverine Vermeire, Remo Panaccione, Gregory T. Moore, Raja Atreya, John Lynch, Melissa G. Marko, Eun Suk Jung, Siyka Alexandrova, Hayley Perry, Marion L. Vetter, Julián Panés
This document will be available on May 2 2026
Efficacy of Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results From the ANTHEM-UC Study
Edward Loftus, Vipul Jairath, Maria Abreu, Minhu Chen, Karen Chachu, Edouard Louis, Jimmy Limdi, Katsuyoshi Matsuoka, Lindsey Surace, Ngozi Erondu, Edmund Arthur, Nicole Houck, Bin Zou, Joyce Zhan, Mary Ellen Frustaci, Grazyna Rydzewska, Britta Siegmund
This document will be available on May 2 2026
Efficacy of Intravenous and Subcutaneous Guselkumab Induction By Weight and Body Mass Index in Patients with Crohn’s Disease: Results From the Phase 3 GALAXI and GRAVITI Studies
Parakkal Deepak, Andres J. Yarur, Tadakazu Hisamatsu, Rian Van Rampelbergh, Wilhelmus van Duijnhoven, Shashi Adsul, Darren Piscitelli, David T. Rubin, Silvio Danese
This document will be available on May 2 2026
Efficacy of Subcutaneous Guselkumab in Moderately to Severely Active Ulcerative Colitis By Induction Week 12 Clinical Response Status: Week 48 Results From the Phase 3 ASTRO Study
Silvio Danese, Millie Long, Laurent Peyrin-Biroulet, Tadakazu Hisamatsu, Thomas Baker, Yelina Alvarez, Lingjing Jiang, Hongyan Zhang, David T. Rubin, Jessica R. Allegretti
This document will be available on May 2 2026
Endoscopic and Histologic Results From the UNITI Jr Study of Ustekinumab in Pediatric Crohn’s Disease
Elisabeth De Greef, Dan Turner, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Richard K. Russell, Stanley A. Cohen, Jeffrey S. Hyams, Anne M. Griffiths, Joel R. Rosh, Richard Strauss, Els Van Limbergen, Omoniyi J. Adedokun, Lilianne Kim, Patrick Branigan, Sheri Volger, Edaire Cheng
This document will be available on May 2 2026
Evaluation of Complete Bowel Symptomatic Remission in Patients with Moderately to Severely Active Ulcerative Colitis
Peter D.R. Higgins, Yelina Alvarez, Thomas Baker, Matthew Germinaro, Robert Fieo, Kelly Kato, Chenglong Han
This document will be available on May 2 2026
Exposure Optimisation Substudy (EOS) of Ustekinumab in Paediatric Ulcerative Colitis (UC): Q4W Results From the Phase 3 UNIFI Jr Study
Elisabeth De Greef, Richard K. Russell, Dan Turner, Anne M. Griffiths, Jeffrey S. Hyams, Stanley A. Cohen, Joel R. Rosh, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Richard Strauss, Els Van Limbergen, Laurie S. Conklin, Omoniyi J. Adedokun, Jose Salas, Yuhua Wang, Paul J. Ufberg
This document will be available on May 2 2026
Extraintestinal Manifestations in Participants with Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GALAXI 2 & 3 Studies
Silvio Danese, Tadakazu Hisamatsu, Rian Van Rampelbergh, Wilhelmus van Duijnhoven, Gustavo Scapini, Shashi Adsul, David T. Rubin
This document will be available on May 2 2026
GUS MOA Video
This video will be available on May 2 2026
Guselkumab for Perianal Fistulizing Crohn’s Disease: Week 24 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter FUZION Study
Laurent Peyrin-Biroulet, Vipul Jairath, Alisa Hart, Geert D’Haens, Axel Dignass, Silvio Danese, Julian Panés, Susan Connor, Walter Reinisch, David Schwartz, Tadakazu Hisamatsu, Bram Verstockt, Antonino Spinelli, Anton Stift, André D’Hoore, Macie J. Nazar,Jacqueline Van Denderen, Talia Gramiccia, Takehiko Sakamoto, Shusheng Xu, Ivana Bravatà, Bruce E. Sands, on behalf of the FUZION Study Group
This document will be available on May 2 2026
Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, Reduces Systemic and Tissue Inflammatory Burden in Ulcerative Colitis: Results From the ANTHEM-UC Study
Edward V. Loftus Jr, Vipul Jairath, Britta Siegmund, Arun K. Kannan, Martha Zeeman, Amy Hart, David Strawn, Swati Venkat, Lynn Tomsho, Bradford McRae, Darren Ruane, Lindsey Surace, Ngozi Erondu, Jia Zhan, Minhu Chen, Karen Chachu, Katsuyoshi Matsuoka, Jimmy Limdi, Grazyna Rydzewska, Maria T. Abreu, Edouard Louis
This document will be available on May 2 2026
Impact of Endoscopic Remission on Long-Term Outcomes and IBD-Related Surgery in Patients with Ulcerative Colitis: A Retrospective Cohort Analysis from the Crohn’s & Colitis Foundation Database
Carla Truyers, Dominik Naessens, Myrlene Sanon, Elise Wu, Jackie Kwong, Shashi Adsul
This document will be available on May 2 2026
Intravenous and Subcutaneous Guselkumab Induction Are Similarly Efficacious in Patients with Ulcerative Colitis Across Weight Quartile and BMI Subgroups: Week 12 Results From the Phase 3 QUASAR and ASTRO Studies
Andres J. Yarur, Parakkal Deepak, Tadakazu Hisamatsu, Yelina Alvarez, Thomas Baker, Shashi Adsul, Darren Piscitelli, Ye Miao, David T. Rubin, Axel Dignass
This document will be available on May 2 2026
Long-term Clinical Outcomes, IBD-Related Surgery, and Steroid Use in Patients with Crohn’s Disease in Endoscopic Remission: A Retrospective Cohort Analysis From the Crohn’s & Colitis Foundation Database
Carla Truyers, Dominik Naessens, Myrlene Sanon, Elise Wu, Jackie Kwong, Shashi Adsul
This document will be available on May 2 2026
Mayo Endoscopic Subscore Changes in Participants with Moderately to Severely Active Ulcerative Colitis Treated with Guselkumab in the QUASAR Long-Term Extension
David T. Rubin, Jessica R. Allegretti, Yelina Alvarez, Thomas Baker, Shashi Adsul, Darren Piscitelli, Ye Miao, Laurent Peyrin-Biroulet
This document will be available on May 2 2026
Pregnancy Outcomes in Maternal Exposure to Guselkumab: Review of Cases Reported to the Company Global Safety Database
Uma Mahadevan, Millie Long, Mette Julsgaard, Connie Lin, Anja Geldhof, Mauricio Rosas Ballina, Hewei Li, Javier P. Gisbert, María Chaparro
This document will be available on May 2 2026
Safety and Efficacy of Ustekinumab in Pediatric Ulcerative Colitis (UC): Results From the Phase 3 UNIFI Jr Study
Elisabeth De Greef, Dan Turner, Richard K. Russell, Anne M. Griffiths4, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Stanley A. Cohen, Jeffrey S. Hyams, Joel R. Rosh, Richard Strauss, Omoniyi J. Adedokun, Jose Salas, Yuhua Wang, Paul J. Ufberg, Els Van Limbergen
This document will be available on May 2 2026
Safety of Guselkumab in Patients Aged ≥60 Years with Immune-Mediated Inflammatory Diseases: A Pooled Analysis of Registrational Trials in UC, CD, PsA and PsO
Adam S. Faye, Shaji Sebastian, Victoria McCaffrey, Ivana Bravatà, Maciej Nazar, Darren Piscitelli, Soumya D. Chakravarty, Shashi Adsul, Jacqueline Yee, Thomas Baker, Bruce E. Sands
This document will be available on May 2 2026
Symptomatic Improvement with Intravenous Guselkumab Induction Therapy is Observed Early in Patients with Moderately to Severely Active Ulcerative Colitis: Post-Hoc Analysis of QUASAR
Axel Dignass, Fumihito Hirai, Masayuki Saruta, Ayako Sasaki, Shinichi Yoshigoe, Jianmin Zhuo, Yishen Yang, Keira Herr, Tadakazu Hisamatsu
This document will be available on May 2 2026
The UNITI Jr Study: Safety and Efficacy Results of Ustekinumab in Paediatric Patients with Crohn’s Disease
Dan Turner, Elisabeth De Greef, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Richard K. Russell, Stanley A. Cohen, Jeffrey S. Hyams, Anne M. Griffiths, Joel R. Rosh, Richard Strauss, Els Van Limbergen, Omoniyi J. Adedokun, Lilianne Kim, Sheri Volger
This document will be available on May 2 2026
Unsupervised Machine Learning to Identify Distinct CDAI-Based Response Patterns to Guselkumab in Participants with Crohn’s Disease: Post Hoc Analysis of the Pooled GRAVITI and GALAXI 2/3 Studies
Stefan Schreiber, Geert D’Haens, Walter Reinisch, Ailsa Hart, Sudheer Rani, Mobolaji Olurinde, Rian Van Rampelbergh, Long-Long Gao, Zijiang Yang, Timothy Hoops, Chandni Valiathan, Parambir S. Dulai
This document will be available on May 2 2026
Ustekinumab Pharmacokinetics and Exposure-Response Relationships in Pediatric Patients with Moderately to Severely Active Crohn’s Disease: Results From UNITI Jr. Phase 3 Study
Omoniyi J. Adedokun, Jingyun Li, Richard S. Strauss, Edaire Cheng, Els Van Limbergen, Sheri Volger, Lilianne Kim, An Vermeulen
This document will be available on May 2 2026
Wearable-Derived Physiologic Signals Differentiate Inflammation From Remission After Biologic Initiation in Inflammatory Bowel Disease
Robert Hirten, Bruce Sands, Mate Suarez- Farinas, MAtteo Danieletto, Andrew Delgado, Dylan Schorr, Drew Helmus, Tim Hewitt, Tiffany Lontoc, Kevin Wilby, Meenakshi Chatterjee, Rana Zia Ur Rehman, Saiyam Jain, Ehsanul Haque, Nikolay Manyakov, Mark Morris, Yanran Huo
This document will be available on May 2 2026
Wearable-Derived Sleep Metrics Identify Responders and Non-Responders Following Biologic Therapy in Inflammatory Bowel Disease
Bruce Sands, Robert Hirten, Matteo Danieletto, Drew Helmus, Tim Hewitt, Dylan Schorr, Meenakshi Chatterjee, Mark Morris, Nikolay Manyakov, Kevin Wilby, Ehsanul Haque Nirjhar, Yanran Wang, Saiyam Jain, Vasanthakumar Thirugnanam, Rana Zia Ur Rehman
This document will be available on May 2 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.